Adaptive Biotechnologies is trading 7.04% lower at $23.50 in pre-market, with no clear company-specific announcement or broader-market move identified to explain the decline.
- An October 14 report covered COO Julie Rubinstein’s sale of 11,881 shares on October 13; the sale was made under a pre-arranged Rule 10b5-1 plan.
- Recent analyst target increases were reported, but neither those reports nor the insider-sale coverage explicitly connects a catalyst to the pre-market move.